Please assess the completion status of the following clinical trial:

Trial Title: Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals with a confirmed COVID-19 viral infection, as determined by a qualified laboratory test. A nasal swab or saliva test analyzed by qPCR for COVID19.~2. Individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study~Exclusion Criteria~1. Viral infections other than COVID-19.~2. Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina~3. Pregnancy~4. Females of child bearing potential age not on adequate contraception or lactating~5. Subjects receiving systemic corticosteroid treatment within one month of Screening Visit~6. Subjects Less than 18 years of age~7. Hospitalization within last 6 months due to acute exacerbation of airway disease~8. Subjects with a clinically significant abnormal chest x-ray within past 12 months~9. Medication changes within one month of study entry~10. Subjects who have participated in another investigation drug treatment study within the previous month.~11. Subjects with a current history of alcohol or recreational drug abuse.~12. Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.~Inclusion of Women and Minorities Every attempt will be made to include all genders, and minorities that present with an active COVID-19 infection that are not exempted due to exclusion criteria.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment of COVID-19 infected patients with a sodium pyruvate nasal spray (Type: EXPERIMENTAL): In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.
- Placebo control treatment of COVID-19 infected patients (Type: PLACEBO_COMPARATOR): In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).